October 30, 2020

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra (East), Mumbai 400 051

Scrip Code: 500325 / 890147
Trading Symbol: RELIANCE / RELIANCEPP

Dear Sirs,

Sub: Monitoring Agency Report for the quarter ended September 30, 2020


The entire funds raised by the Company through Rights Issue, including amount received during the quarter ended September 30, 2020, has been utilized for the objects stated in the Letter of Offer for Rights Issue of the Company, dated May 15, 2020.

Request you to please take the above on record.

Thanking you,

Yours faithfully,
For Reliance Industries Limited

Savitri Parekh
Joint Company Secretary and Compliance Officer

Encl.: as above

Copy to:
The Luxembourg Stock Exchange
Societe de la Bourse de Luxembourg
35A boulevard Joseph II
B P 165, L-2011 Luxembourg

Singapore Stock Exchange
2 Shenton Way, #19- 00 SGX Centre 1,
Singapore 068804
To,
Reliance Industries Limited
3rd Floor, Maker Chambers IV
222, Nariman Point
Mumbai 400 021
Maharashtra, India

Kind Attn: Ms. Savithri Parekh

Dear Madam,

Sub.: Monitoring Agency Report for the quarter ended September 2020 - in relation to the Rights Issue of Reliance Industries Limited (“the Company”)

We write in our capacity of Monitoring Agency for the Rights Issue for the amount aggregating Rs. 53,124.20 crore (raised till September 30, 2020 is Rs. 13,281.05 crore) of the Company and refer to our duties cast under Regulation 82(2) of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations, 2018.

In this connection, we are enclosing the Monitoring Agency Report for the quarter ended September 30, 2020 as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated May 15, 2020.

Request you to kindly take the same on records.

Thanking you,
For Axis Bank Limited

Authorised Signatory
REPORT OF THE MONITORING AGENCY

Name of the issuer: Reliance Industries Limited

For quarter ended: September 30, 2020

Name of the Monitoring Agency: Axis Bank Limited

   a) Deviation from the objects: There is no deviation.

   b) Range of Deviation: Not applicable

Declaration:

We hereby declare that this report is based on the format prescribed by the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended. We further declare that this report provides a true and fair view of the utilization of the issue proceeds.

We declare that we do not have any direct / indirect interest in or relationship with the issuer / promoters / directors / management and also confirm that we do not perceive any conflict of interest in such relationship / interest while monitoring and reporting the utilization of the issue proceeds by the issuer.

For and on behalf of Axis Bank Limited
(in capacity as Monitoring Agency)

________________________
(Authorised Signatory)
Name: Mangalagowari Bhat
Date: 30th October, 2020
1. **Issuer Details:**
   - Name of the issuer: Reliance Industries Limited
   - The names of the promoters of the issuer: Shri Mukesh D. Ambani
   - Industry/sector to which it belongs: Refining, Petrochemicals (Polymers, Polyester and Fibre Intermediates), Exploration and Production of Oil & Gas and Textiles

2. **Issue details**
   - Issue Period: May 20, 2020 to June 03, 2020
   - Type of issue (rights): Rights issue
   - Type of specified securities: Equity shares (Partly Paid up)
   - Grading, if any: Not Applicable
   - Issue size (₹ in Crores): Rs. 53,124.20 crore (Note 1)

**Note 1:**

<table>
<thead>
<tr>
<th>No of Equity shares</th>
<th>Price (in Rs.)</th>
<th>Amount (Rs in crore)</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Issue Size</td>
<td></td>
<td></td>
<td>We understand that the Rights Equity Shares were issued as partly paid-up and an amount of Rs. 314.25 (i.e. 25% of the Issue Price) per Rights Equity Share has been received on application (of which Rs. 2.50 towards face value of Rights Equity Share and Rs. 311.75 towards premium amount of Rights Equity Share). The schedule for payment of the balance amount of Rs. 942.75 per Rights Equity Share is proposed as (i) Rs. 314.25 i.e. 25% in May 2021; and (ii) Rs. 628.50 i.e. the balance 50% in November 2021. The Board of the Company would make the calls for this purpose.</td>
</tr>
<tr>
<td>42,24,40,258</td>
<td>314.25</td>
<td>13,275.19#</td>
<td></td>
</tr>
<tr>
<td>1,86,636</td>
<td>314.25</td>
<td>5.86@</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td><strong>Rs. 53,124.20</strong></td>
<td></td>
</tr>
</tbody>
</table>

# Rounded off to two decimal places

@ Total amount received during the quarter ended September 30, 2020 is Rs. 5,86,50,363.

**Note 2:**

We understand that issue of 1,86,636 Rights Equity Shares, kept in abeyance pursuant to an order passed by the Hon’ble Special Court constituted under the Special Court (Trial of Offences Relating to Transactions in Securities) Act, 1992, were allotted on July 29, 2020 to the eligible applicants in accordance with the order passed by the Hon’ble Special Court.
3. **Details of the arrangement made to ensure the monitoring of issue proceeds:**

<table>
<thead>
<tr>
<th>Particulars</th>
<th>Reply</th>
<th>Comments of the Monitoring Agency</th>
<th>Comments of the Board of Directors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whether all utilisation is as per the disclosure in the offer document?</td>
<td>Yes/ No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Whether shareholders’ approval has been obtained in case of material deviations# from expenditures disclosed in the offer document?</td>
<td>Yes/ No</td>
<td>Not applicable</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Whether the means of finance for the disclosed objects of the Issue has changed?</td>
<td>Yes/ No</td>
<td>Not applicable</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Is there any major deviation(s) observed over the earlier monitoring agency reports?</td>
<td>Yes/ No</td>
<td>No, there are no deviations.</td>
<td>No, there are no deviations.</td>
</tr>
<tr>
<td>Whether all government/ statutory approvals related to the object(s) have been obtained?</td>
<td>Yes/ No</td>
<td>Not applicable</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Whether all arrangements pertaining to technical assistance/collaboration are in operation?</td>
<td>Yes/ No</td>
<td>Not applicable</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Are there any favorable events improving the viability of these objects?</td>
<td>Yes/ No</td>
<td>Not applicable</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Are there any unfavorable events affecting the viability of the objects?</td>
<td>Yes/ No</td>
<td>Not applicable</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Is there any other relevant information that may materially affect the decision making of the investors?</td>
<td>Yes/ No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

#Where material deviation may be defined to mean:
(a) Deviation in the objects or purposes for which the funds have been raised
(b) Deviation in the amount of fund actually utilized by more than 10% of the amount projected in the offer documents.

4) **Details of object(s) to be monitored:**

(i) Cost of object(s)- The object of the utilisation is “Repayment/ prepayment of all or a portion of certain borrowings availed by the Company and General corporate purposes.”

<table>
<thead>
<tr>
<th>S. No</th>
<th>Item Head</th>
<th>Original Cost (as per Offer Document) (Rs in crore)</th>
<th>Revised Cost</th>
<th>Comments of the Monitoring Agency</th>
<th>Comments of the Board of Directors</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Repayment/ prepayment of all or a portion of certain borrowings availed by the Company</td>
<td>39,755.08</td>
<td>Not applicable</td>
<td>NIL</td>
<td>Not applicable</td>
</tr>
<tr>
<td>2</td>
<td>General corporate purposes</td>
<td>13,281.05</td>
<td>Not applicable</td>
<td></td>
<td>Not applicable</td>
</tr>
</tbody>
</table>
(ii) Progress in the object(s)-

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Item Head</th>
<th>Amount as proposed in Offer Document</th>
<th>Amount utilized#</th>
<th>Total unutilized amount</th>
<th>Comments of the Monitoring Agency</th>
<th>Comments of the Board of Directors</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Repayment/prepayment of all or a portion of certain borrowings availed by the Company</td>
<td>39,755.08</td>
<td>13,275.19</td>
<td>5.86</td>
<td>13,281.05</td>
<td>NIL</td>
</tr>
<tr>
<td></td>
<td>General corporate purposes</td>
<td>13,281.05</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

# The total funds raised from the Rights Issue till September 30, 2020 is Rs 13,281,05,01,439.50 including an amount of Rs 5,86,50,363 received during the quarter ended September 30, 2020 (Refer note 1 above for details).

(iii) Deployment of unutilized Issue Proceeds- Not applicable

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Type of instrument where amount invested*</th>
<th>Amount invested</th>
<th>Maturity Date</th>
<th>Earnings</th>
<th>Return on Investment (ROI %)</th>
<th>Market value as at the end of quarter**</th>
</tr>
</thead>
</table>

* Also indicate name of the party/company in which amounts have been invested

**Where market value is not practical to find, provide NAV/NRV/Book value of the same

(iv) Delay in implementation of the object(s)-Not applicable

<table>
<thead>
<tr>
<th>Object(s) Name</th>
<th>Completion Date</th>
<th>Delay (No. of days/months)</th>
<th>Comments of the Board of Directors</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>As per Offer Document</td>
<td>Actual*</td>
<td>Reason of delay</td>
</tr>
</tbody>
</table>

*In case of continuing object(s) please specify latest/revised estimate of the completion date.